Targeted disruption of CD44 in MDAY-D2 lymphosarcoma cells has no effect on subcutaneous growth or metastatic capacity - PubMed (original) (raw)

Targeted disruption of CD44 in MDAY-D2 lymphosarcoma cells has no effect on subcutaneous growth or metastatic capacity

M H Driessens et al. J Cell Biol. 1995 Dec.

Abstract

CD44 splice variants have been shown to be involved in metastasis of carcinomas. In addition, the standard form of CD44 has been implicated in metastasis, particularly of melanomas and lymphomas. To investigate this, we have generated a CD44-negative mutant of the highly metastatic murine MDAY-D2 lymphosarcoma. The two CD44 alleles of this diploid cell line were sequentially disrupted by homologous recombination, using isogenic CD44 genomic constructs interrupted by a neomycin or hygromycin resistance-conferring gene. The resulting double knockout (DKO) cells had completely lost the capacity to bind to immobilized hyaluronic acid, but did not differ from MDAY-D2 cells in integrin expression or in vitro growth. Subcutaneous (s.c.) growth potential and metastatic capacity of MDAY-D2 and DKO cells were assessed by s.c. and i.v. injection of the lowest cell dose (10(3) or 10(4), respectively) that gave rise to tumor formation by MDAY-D2 cells in approximately 100% of the mice. Quite unexpectedly, we observed no difference at all in either s.c. growth rate or local invasion into surrounding tissues between MDAY-D2 cells and the CD44-negative DKO cells. Also hematogenous metastasis formation upon i.v. injection was similar: both parental and DKO cells metastasized extensively to the spleen, liver, and bone marrow. We conclude that, at least for these MDAY-D2 lymphosarcoma cells, the standard form of CD44 is dispensable for tumor growth and metastasis. Our results show that targeted disruption of genes in tumor cells is a feasible approach to study their role in tumorigenesis and metastasis.

PubMed Disclaimer

Cited by

A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity.
Barghout SH, Aman A, Nouri K, Blatman Z, Arevalo K, Thomas GE, MacLean N, Hurren R, Ketela T, Saini M, Abohawya M, Kiyota T, Al-Awar R, Schimmer AD. Barghout SH, et al. JCI Insight. 2021 Mar 8;6(5):e141518. doi: 10.1172/jci.insight.141518. JCI Insight. 2021. PMID: 33476303 Free PMC article.
Animal Models of Bone Metastasis.
Simmons JK, Hildreth BE 3rd, Supsavhad W, Elshafae SM, Hassan BB, Dirksen WP, Toribio RE, Rosol TJ. Simmons JK, et al. Vet Pathol. 2015 Sep;52(5):827-41. doi: 10.1177/0300985815586223. Epub 2015 May 28. Vet Pathol. 2015. PMID: 26021553 Free PMC article. Review.
Differential expression of CD44 variants among meningioma subtypes.
Suzuki SO, Iwaki T, Kitamoto T, Mizoguchi M, Fukui M, Tateishi J. Suzuki SO, et al. Clin Mol Pathol. 1996 Jun;49(3):M140-6. doi: 10.1136/mp.49.3.m140. Clin Mol Pathol. 1996. PMID: 16696062 Free PMC article.
The CD44v7/8 epitope as a target to restrain proliferation of fibroblast-like synoviocytes in rheumatoid arthritis.
Wibulswas A, Croft D, Bacarese-Hamilton I, McIntyre P, Genot E, Kramer IM. Wibulswas A, et al. Am J Pathol. 2000 Dec;157(6):2037-44. doi: 10.1016/S0002-9440(10)64842-0. Am J Pathol. 2000. PMID: 11106576 Free PMC article.
CD44 cell adhesion molecules.
Goodison S, Urquidi V, Tarin D. Goodison S, et al. Mol Pathol. 1999 Aug;52(4):189-96. doi: 10.1136/mp.52.4.189. Mol Pathol. 1999. PMID: 10694938 Free PMC article. Review.

References

1. J Histochem Cytochem. 1986 Aug;34(8):1037-46 - PubMed
1. Int J Cancer. 1978 Nov 15;22(5):583-94 - PubMed
1. Blood. 1989 Mar;73(4):885-8 - PubMed
1. J Cell Biol. 1989 May;108(5):1979-85 - PubMed
1. J Immunol. 1989 Aug 1;143(3):798-801 - PubMed

Targeted disruption of CD44 in MDAY-D2 lymphosarcoma cells has no effect on subcutaneous growth or metastatic capacity - PubMed (original) (raw)